Review: SIRT1–microRNA networks across stages of chronic liver disease
This review proposes that microRNAs acting on sirtuin 1 (SIRT1) converge mechanistically across stages of chronic liver injury, from fat accumulation to liver cancer; experimental support exists, but clinical validation is insufficient. [1]
Automatic summary · not editorially reviewed
The key findings
The review treats steatotic liver disease, hepatotoxicity, fibrosis and hepatocellular carcinoma as stages of chronic liver injury involving metabolic dysregulation, inflammation, oxidative stress and cellular senescence. [1]
The authors propose that microRNAs act through modulation of SIRT1, and abnormal SIRT1–miRNA network function is implicated in lipid accumulation, fibrogenesis and tumour development. [1]
Experimental studies are said to support the axis biologically, while disease heterogeneity, cell-specific targeting, delivery limitations and insufficient clinical validation remain. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- Not applicable; a narrative review of liver disease biology, not a study population.
- Summary based on
- Study abstract
- Original publication
- September 22, 2026
SIRT1–miRNA axis across liver disease stages
The review covers metabolic dysfunction-associated steatotic liver disease, drug-related liver injury, liver fibrosis and hepatocellular carcinoma as stages of chronic liver injury shaped by metabolic dysregulation, inflammation, oxidative stress and cellular senescence. It proposes that microRNAs, which regulate these processes, act by modulating SIRT1, described as a metabolic and stress-response sensor. Abnormal SIRT1–miRNA network function is implicated in lipid accumulation, mitochondrial dysfunction, immune-cell activation, stellate-cell transdifferentiation, fibrogenesis and tumour development.
Supporting source [1]
Proposed convergence and stage-specific SIRT1 roles
Unlike earlier reviews that treated individual microRNAs and diseases separately, this review focuses on mechanistic convergence and on how SIRT1 works differently at different disease stages. It also considers cellular senescence, an immunometabolic switch, communication via exosomes and the role of SIRT1 in hepatocellular carcinoma development, and analyses how microRNA regulation of SIRT1 affects metabolic adaptation and fibrogenesis. The authors note a pharmacological tension: separating beneficial effects of SIRT1 activation in metabolic liver disease from harmful effects in more advanced hepatocellular carcinoma.
Supporting source [1]
Experimental support versus translational gaps
The authors state that experimental studies consistently support the biological significance of the SIRT1–miRNA axis. They list remaining translational challenges: disease heterogeneity, cell-specific targeting, delivery limitations and insufficient clinical validation. They suggest that combining multiomics technologies, circulating microRNA biomarkers and precision-medicine approaches may improve understanding of SIRT1-centred networks and support more effective therapeutic strategies. These are proposals for future work, not validated treatments.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. It summarises proposed mechanisms and experimental findings, not new human trials, and the authors themselves note insufficient clinical validation.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
El-Sehrawy AAMA, Radhie SH, Baig MR, Mansurov D, M M R, Nayak PP, Bainsal N, Singhal D, Smerat A, Almajar M. · europepmc.org · September 22, 2026